ME03033B - Peptidi derivati ezrina 1 njihove farmaceutske kompozicije - Google Patents

Peptidi derivati ezrina 1 njihove farmaceutske kompozicije

Info

Publication number
ME03033B
ME03033B MEP-2018-96A MEP201896A ME03033B ME 03033 B ME03033 B ME 03033B ME P201896 A MEP201896 A ME P201896A ME 03033 B ME03033 B ME 03033B
Authority
ME
Montenegro
Prior art keywords
ezrina
pharmaceutical compositions
peptides derivatives
peptides
derivatives
Prior art date
Application number
MEP-2018-96A
Other languages
German (de)
English (en)
French (fr)
Inventor
Rupert Holms
Ravshan Ataullakhanov
Rustam Ataullakhanov
Khachik Sayadyan
Original Assignee
Nearmedic International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nearmedic International Ltd filed Critical Nearmedic International Ltd
Publication of ME03033B publication Critical patent/ME03033B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4735—Villin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MEP-2018-96A 2015-06-01 2016-06-01 Peptidi derivati ezrina 1 njihove farmaceutske kompozicije ME03033B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2015120667 2015-06-01
EP16728271.4A EP3191504B1 (en) 2015-06-01 2016-06-01 Ezrin-derived peptides and pharmaceutical compositions thereof
PCT/EP2016/062336 WO2016193285A1 (en) 2015-06-01 2016-06-01 Ezrin-derived peptides and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ME03033B true ME03033B (me) 2018-10-20

Family

ID=56117690

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-96A ME03033B (me) 2015-06-01 2016-06-01 Peptidi derivati ezrina 1 njihove farmaceutske kompozicije

Country Status (26)

Country Link
US (1) US9682140B2 (me)
EP (1) EP3191504B1 (me)
JP (1) JP6721419B2 (me)
KR (1) KR101842978B1 (me)
CN (1) CN106188267B (me)
AU (1) AU2016203656B2 (me)
CA (1) CA2931875C (me)
CY (1) CY1120501T1 (me)
DK (1) DK3191504T3 (me)
ES (1) ES2660894T3 (me)
GB (1) GB2546439B (me)
HR (1) HRP20180560T1 (me)
HU (1) HUE038737T2 (me)
LT (1) LT3191504T (me)
MA (1) MA39421A (me)
MD (1) MD3191504T2 (me)
ME (1) ME03033B (me)
MX (1) MX377333B (me)
PL (1) PL3191504T3 (me)
PT (1) PT3191504T (me)
RS (1) RS57067B1 (me)
SG (1) SG10201604401UA (me)
SI (1) SI3191504T1 (me)
SM (1) SMT201800190T1 (me)
WO (1) WO2016193285A1 (me)
ZA (1) ZA201603723B (me)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
CN106596977B (zh) * 2017-02-08 2018-06-08 南京医科大学第一附属医院 ezrin在制备哮喘诊断试剂中的应用
WO2021198346A2 (en) 2020-04-01 2021-10-07 Dr. Nesselhut Besitzgesellschaft Mbh Ezrin peptide 1 for use in a method of treating covid-19
EP4125996B1 (en) * 2020-04-01 2024-08-28 Pantapharm AG Ezrin peptide 1 for use in a method of treating covid-19
CA3212362A1 (en) 2021-03-31 2022-10-06 Thomas Nesselhut Ezrin peptide 1 for use in a method of treating post covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290293A (en) 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin
GB0301879D0 (en) 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
WO2007060440A2 (en) 2005-11-23 2007-05-31 Regent Research L.L.P. The use of peptides in anti-ulcer therapy

Also Published As

Publication number Publication date
MX377333B (es) 2025-03-06
CA2931875C (en) 2022-06-21
SI3191504T1 (en) 2018-04-30
WO2016193285A1 (en) 2016-12-08
HRP20180560T1 (hr) 2018-05-04
KR101842978B1 (ko) 2018-03-29
BR102016012501A2 (pt) 2020-04-28
JP2017025055A (ja) 2017-02-02
DK3191504T3 (en) 2018-04-30
NZ720748A (en) 2023-09-29
CN106188267B (zh) 2020-11-06
CY1120501T1 (el) 2019-07-10
MD3191504T2 (ro) 2018-04-30
ES2660894T3 (es) 2018-03-26
AU2016203656A1 (en) 2016-12-15
MA39421A (fr) 2017-07-19
AU2016203656B2 (en) 2020-02-06
RS57067B1 (sr) 2018-06-29
MX2016007122A (es) 2017-01-25
US20160346383A1 (en) 2016-12-01
PL3191504T3 (pl) 2018-08-31
CA2931875A1 (en) 2016-12-01
EP3191504A1 (en) 2017-07-19
US9682140B2 (en) 2017-06-20
ZA201603723B (en) 2019-03-27
JP6721419B2 (ja) 2020-07-15
GB2546439A (en) 2017-07-19
PT3191504T (pt) 2018-04-16
HUE038737T2 (hu) 2018-11-28
GB2546439B (en) 2020-08-26
KR20160141673A (ko) 2016-12-09
LT3191504T (lt) 2018-04-10
SG10201604401UA (en) 2017-01-27
GB201705990D0 (en) 2017-05-31
EP3191504B1 (en) 2018-01-17
CN106188267A (zh) 2016-12-07
SMT201800190T1 (it) 2018-05-02

Similar Documents

Publication Publication Date Title
KR102281667B9 (ko) 아트로핀 약학 조성물 (atropine pharmaceutical compositions)
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3655017T3 (da) Farmaceutisk sammensætning
EP3513809A4 (en) MEDICAL COMPOSITION
EP3641771A4 (en) PHARMACEUTICAL COMPOSITIONS
PT3297605T (pt) Composições farmacêuticas tópicas
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
PT4070788T (pt) Formulações farmacêuticas
DK3089741T3 (da) Farmaceutiske sammensætninger omfattende azd9291
BR112018000054A2 (pt) composições farmacêuticas liofilizadas
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
DK3634377T3 (da) Farmaceutisk formulering
EP3603642A4 (en) PHARMACEUTICAL PREPARATION
PL3509573T3 (pl) Kompozycje farmaceutyczne do dostarczania peptydu
DK3278801T3 (da) Farmaceutisk sammensætning indeholdende mirabegron
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
DK3583943T3 (da) Farmaceutisk sammensætning
DK3280447T3 (da) Farmaceutiske formuleringer
DK3389633T3 (da) Farmaceutiske sammensætninger, der omfatter phenylaminopyrimidinderivat
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
SMT202400478T1 (it) Composizione farmaceutica
GB2546439B (en) Ezrin-derived peptides and pharmaceutical compositions thereof
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf
DK3302483T3 (da) Farmaceutiske sammensætninger og anvendelse deraf
EP3727485C0 (en) PHARMACEUTICAL COMPOSITION